The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHIO | -31.21% | -99.09% | -60.87% | -100% |
| S&P | +19.89% | +109.18% | +15.89% | +404% |
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $11.28M | 254.9% |
| Market Cap / Employee | $2.26M | 0.0% |
| Employees | 5 | -44.4% |
| Net Income | -$2.17M | -17.3% |
| EBITDA | -$2.31M | -20.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.78M | 129.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -85.38% | 13.2% |
| Return On Invested Capital | -104.41% | -1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.54M | -43.1% |
| Operating Free Cash Flow | -$2.54M | -42.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.47 | 0.35 | 0.48 | 0.92 | 62.76% |
| Price to Tangible Book Value | 0.47 | 0.35 | 0.48 | 0.92 | 62.76% |
| Enterprise Value to EBITDA | 1.24 | 1.35 | 4.10 | -0.21 | -126.85% |
| Return on Equity | -122.0% | -114.8% | -76.1% | -102.2% | -19.45% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
